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Purpose	
Community-acquired pneumonia (CAP) is commonly diagnosed in the primary care setting.
Management of nonresponsive pneumonia (NRP), i.e. failure to respond to CAP treatment, is not
clearly understood. The purpose of this study was to describe the initial work-up and treatment of CAP
in the ambulatory primary care setting and to determine relative proportion of, diagnostic approach to
and treatment of NRP.
Methods	
We retrospectively studied adult patients diagnosed with CAP within our large, integrated health care
system from October 2006 through July 2013. Cases were defined as patients with CAP who worsened
after 4 days, or did not improve within 10 days, of antibiotic treatment. Controls were CAP patients who
did not meet case definition. Mann-Whitney and t-tests were used to analyze continuous variables.
Chi-square or Fisher’s exact test was used to analyze categorical variables. Significant variables were
used to construct a multivariable logistic regression model.
Results		Of 250 total patients studied, there were 85 cases and 165 controls. The case population was significantly
older (59 ± 16 vs. 53 ± 19 years, P=0.02). Multivariable logistic regression revealed former smoker
(P<0.01), initial presentation to urgent care (P=0.02) and myalgia (P=0.003) as predictors of NRP. Chest
X-rays were more commonly ordered for cases at initial visit (80% vs. 68%, P=0.06). Overall, 24% of
patients had additional testing at the initial visit (39% of cases vs. 16% of controls, P<0.001). Additionally,
a higher proportion of cases underwent antibiotic change at their first (62% vs. 15%, P<0.001) or second
(47% vs. 5%, P<0.001) follow-up visit.
Conclusions	
Patients with NRP tended to be former smokers, report myalgia and/or present to urgent care. The
majority of providers conducted chest X-rays, but no further pneumonia testing, at the initial visit.
Further study is needed to determine if this strategy leads to delayed etiologic diagnosis and definitive
treatment. (J Patient Cent Res Rev. 2016;3:79-89.)
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Community-acquired pneumonia (CAP) is a common
infectious disease that is frequently diagnosed by
primary care clinicians. In the United States, more than
4 million cases of pneumonia present to ambulatory
health centers annually and rely on primary care
clinicians (i.e. those in family medicine, internal
medicine and urgent care) as their first point of contact.1
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Milwaukee, WI, 53233, T: 414-219-5191, F: 414-219-3116,
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A 2002 publication from the Agency for Healthcare
Research and Quality emphasized the safety and cost
savings of outpatient versus inpatient treatment for
CAP (average cost of outpatient case was $300 vs.
$5,700 for inpatient case).2 Older studies also have
confirmed the safety of initial outpatient treatment
for CAP in persons deemed to be at low risk for
complications.3-5 Nonetheless, the primary care
setting creates a difficult environment in which to
diagnose pneumonia due to the reliance on patient
history and physical examination and, frequently, the
lack of on-site chest radiographs.6
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Nonresponsive pneumonia (NRP) occurs when
treatment for CAP fails despite an administered
antibiotic regimen, and results in worsening symptoms
or delayed achievement of clinical stability.7 NRP is
multifactorial and associated with increased morbidity,
mortality and costs.7-11 Recent studies of NRP have
all involved hospitalized patients.7-10,12-17 Thus, little is
known about NRP in patients initially seen in a primary
care ambulatory clinic.

CAP patients who did not meet the case definition
(i.e. had stable signs or symptoms within 4 days of
antibiotic treatment and/or improved within 10 days
of antibiotic treatment). Patients with CAP who were
treated with antibiotics and not expected to make a
follow-up visit but advised to return if there was no
improvement were considered control subjects if they
did not further encounter our integrated health system
for that pneumonia illness.

The purpose of this study was to assess how primary
care clinicians managed CAP cases that presented
in the ambulatory setting and determine the relative
proportion and characteristics of NRP in the outpatient
population. In addition, we aimed to describe how
NRP initially presenting in the outpatient setting is
addressed through additional diagnostic work-up or
changes in treatment.

Variables obtained from the medical records included
basic demographic data, smoking status, comorbid
conditions, presenting and follow-up respiratory
and constitutional signs and symptoms, vital signs,
timing of follow-up visits, related laboratory and
radiologic test results, type and timing of antibiotic
therapy, and the final most specific diagnosis for the
medical condition that prompted the initial clinical
or radiologic diagnosis of pneumonia. For purposes
of this retrospective study, we considered clinical
signs and symptoms present if they were recorded in
the medical record and absent if they were not. The
first author either personally reviewed each medical
record examined for this study or closely supervised
the record review process. Subjects with uncategorized
clinical features were included following consensus by
the first and third authors.

METHODS

Data Sources and Subject Selection
A retrospective unmatched case-control study of
250 subjects aged 18 years or more who had CAP
diagnosed by a primary care clinician in an outpatient
facility from October 2006 through July 2013 was
conducted. Randomly sorted electronic medical
records were obtained by the research analytics team
at our institution, a large health system that includes
15 hospitals and more than 150 outpatient clinics.
Subjects were identified from all outpatient facilities
by ICD-9 pneumonia diagnostic codes 480–486 (and
subsets). Patients who had documented CAP diagnosis
by either clinical or radiographic impressions were
included in this study. Excluded patients were those
who had no substantiation of CAP diagnosis by the
treating clinician, initially presented to an emergency
department or a non-primary care specialist, were
ultimately diagnosed with medical facility-acquired
pneumonia, or had incomplete records. Additionally,
patients with any of the following diagnoses were
excluded: cancer, bronchiectasis, blood dyscrasia,
tuberculosis, HIV/AIDS or tracheostomy/ventilator
dependence. Pregnant women also were excluded.
Cases of NRP were defined as individuals with CAP
who had worsening vital signs, symptoms or clinical
findings after 4 days, or who did not improve within
10 days, of antibiotic treatment. Control subjects were
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All activities were reviewed and approved by the local
institutional review board.
Statistical Analysis
Minitab® statistical software (Release 13, State
College, PA) was used for data analysis. Summary
statistics were calculated. Categorical data was
analyzed using chi-square tests with Yates’ correction
or Fisher’s exact test, as appropriate. Continuous
variables were analyzed using two-sample t-tests or
the Mann-Whitney test. Binary logistic regression was
used for multivariable analysis of NRP cases versus
controls, utilizing only variables that were significant
on univariable analysis. P-values less than 0.05 were
considered statistically significant.

RESULTS

A total of 991 electronic medical records of
unique adult patients associated with a diagnosis
of pneumonia in an outpatient department of our
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health system were identified. Of those records, 398
were excluded for lacking confirmation of clinician
diagnosis of acute CAP. Of the 593 patients with CAP,
84 were excluded due to incomplete medical records
and 259 were excluded due to initial presentation
to a specialist physician or emergency department
and/or other exclusion criteria detailed in Methods.
Therefore, 250 patients met study inclusion criteria.
There were 85 cases of NRP, or 34% of those with
CAP originally diagnosed in an outpatient facility by
the primary care clinician. NRP cases were compared
to the 165 control patients with CAP (Table 1). Our
study population was predominantly Caucasian
(88%), female (54%) and nonsmokers (76%), and most
often initially presented to a family medicine clinic

(43%). Specificity of initial pneumonia diagnosis
did not vary between controls and cases, with 86%
of controls and 85% of cases given “communityacquired pneumonia,” “pneumonia not otherwise
specified” or related codes. Due to the fact that our
medical system was continually adding primary care
clinics to the electronic medical record during the
study time period, 70% of included subject records
were from the years 2012–2013. Cases did not differ
from controls with respect to seasonal distribution
using National Weather Service definitions18 (26%
vs. 34% for December–February, 45% vs. 38% for
March–May, 16% vs. 15% for June–August, 13%
vs. 13% for September–November; P=0.59), nor by
proportion seen during cold weather months (54% vs.
56% for October–March, P=0.77).

Table 1. Comparison of features of subjects with CAP: cases vs. controls
Feature
Mean age ± SD, years
Female
Race/ethnicity
White
Black
Hispanic
Other
Current smoking
Former smoker
Asthma
Chronic bronchitis
COPD
Other lung disease
Chronic sinusitis
Congestive heart failure
Other heart disease
Chronic kidney disease
Diabetes mellitus
Urgent care§

NRP cases
(N=85)

CAP controls
(N=165)

Odds
ratio

All subjects
(N=250)

58.8 ± 15.5
46 (54%)

53.4 ± 18.8
90 (55%)

0.98*

55.3 ± 17.9
136 (54%)

79 (93%)
3 (4%)
2 (2%)
1 (1%)
18 (21%)
38 (45%)
16 (19%)
6 (7%)
15 (18%)
6 (7%)
6 (7%)
6 (7%)
19 (22%)
9 (11%)
17 (20%)
28 (33%)

141 (85%)
10 (6%)
9 (5%)
5 (3%)
41 (25%)
42 (25%)
36 (22%)
8 (5%)
22 (13%)
4 (2%)
7 (4%)
8 (5%)
23 (14%)
7 (4%)
25 (15%)
33 (20%)

2.24
0.57
0.42
0.38
0.94
2.37†
0.83
1.49
1.39
3.06
1.71
1.49
1.78
2.67
1.40
1.96‡

220 (88%)
13 (5%)
11 (4%)
6 (2%)
59 (24%)
80 (32%)
52 (21%)
14 (6%)
37 (15%)
10 (4%)
13 (5%)
14 (6%)
42 (17%)
16 (6%)
42 (17%)
61 (24%)

Values are presented as n (%) unless otherwise noted.
*P=0.02, two-sample t-test.
†

P=0.003, chi-square test with Yates’ correction.

‡

P=0.03, chi-square test with Yates’ correction.

§

Patients who presented to urgent care for initial diagnosis (vs. office setting).

CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; NRP, nonresponsive pneumonia;
SD, standard deviation.
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On univariable analyses, demographic data, recorded
clinical signs and initial diagnostic testing showed
significant associations with NRP (Tables 2 and 3).
The NRP case group was significantly older (58.8 ±
15.5 vs. 53.4 ± 18.8, P=0.02), had a higher proportion
of former smokers (45% vs. 25%, P=0.003) and
was more likely to initially present to an urgent care
setting (33% vs. 20%, P=0.03). Patients with NRP
were significantly more likely than control patients
to present with myalgia (28% vs. 15%, P=0.01). The
mean duration of cough was longer in cases compared
to controls, but this difference was not significant (11.7
vs. 9.5 days, P=0.09). Median respiratory rate was
higher and median oxygen saturation was lower in
NRP patients; however, not all patients had these vital
signs recorded (Table 3).

chest X-rays were no more likely to be ordered in
urgent care than an office setting (74% vs. 71%,
P=0.8) or to be read as negative (7% vs. 16%, P=0.5).
Initial radiographs were not significantly less likely
to be read as negative for cases compared to controls
(6% [4/68] vs. 13% [15/112], P=0.1). Overall, 24% of
the patients had additional testing at the initial visit,
39% (n=33) of cases and 16% (n=27) of controls
(P<0.001). Specific types of additional testing
did not differ significantly, with cases undergoing
more biochemical (33% vs. 26%, P=0.73) and
hematological (36% vs. 29%, P=0.78) laboratory
tests than controls and controls undergoing more
radiographic (including X-rays and CT scans, 26%
vs. 18%, P=0.68) and microbiologic (19% vs. 12%,
P=0.72) tests than cases.

Chest X-rays were more commonly ordered for cases
than controls at the initial visit, but this difference
was not significant (80% vs. 68%, P=0.06). Initial

Only 1% of all subjects had an initial sputum culture
and gram stain. At the initial visit, 1 NRP case and 4
controls had Streptococcus pneumoniae antigen testing,

Table 2. Comparison of presenting symptoms of subjects with CAP: cases vs. controls
Symptom
Fever
Chills
Cough
Mean duration of
cough ± SD, days
Hemoptysis
Chest pain
Chest congestion
Dark-colored sputum
Dyspnea
Head congestion
Sinus pain
Rhinorrhea
Sore throat
Night sweats
Fatigue
Malaise
Myalgia
Headache

NRP cases
(N=85)

CAP controls
(N=165)

Odds
ratio

All subjects
(N=250)

40 (47%)
25 (29%)
78 (92%)

73 (44%)
47 (28%)
160 (97%)

1.12
1.05
0.35

113 (45%)
72 (29%)
238 (95%)

11.7 ± 9.9

9.5 ± 8.8

7 (8%)
19 (22%)
21 (25%)
35(41%)
41 (48%)
17 (20%)
7 (8%)
13 (15%)
18 (21%)
12 (14%)
29 (34%)
20 (24%)
24 (28%)

7 (4%)
35 (21%)
40 (24%)
86 (52%)
76 (46%)
38 (23%)
20 (12%)
44 (27%)
41 (25%)
25 (15%)
45 (27%)
28 (17%)
24 (15%)

2.03
1.07
1.03
0.64
1.09
0.84
0.65
0.5
0.81
0.92
1.38
1.51
2.31*

14 (6%)
54 (22%)
61 (24%)
121 (48%)
117 (47%)
55 (22%)
29 (12%)
57 (23%)
59 (24%)
37 (15%)
74 (30%)
48 (19%)
48 (19%)

14 (16%)

33 (20%)

0.79

47 (19%)

10.2 ± 9.2

Values are presented as n (%) unless otherwise noted.
*P=0.01, chi-square test with Yates’ correction.
CAP, community-acquired pneumonia; NRP, nonresponsive pneumonia; SD, standard deviation.
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Table 3. Comparison of recorded presenting signs and diagnostic testing of subjects with CAP: cases vs. controls
Sign/diagnostic test
Mean max. temperature ± SD, °F
Mean heart rate ± SD, bpm
Median respiratory rate, rpm
Median oxygen saturation, %
Decreased breath sounds
Dullness to percussion
Rales/crackles
Rhonchi
Wheezes
Chest X-ray
Chest CT scan
White blood cell count
Sputum culture

NRP cases
(N=85)

CAP controls
(N=165)

Odds
ratio

All subjects
(N=250)

99.6 ± 2.0
(n=61)
87.5 ± 20.1
(n=70)
20.0* (n=47)
93.5† (n=44)
11 (13%)
3 (4%)
23 (27%)
17 (20%)
26 (31%)
68 (80%)
4 (5%)
21 (25%)

99.5 ± 1.7
(n=115)
85.2 ± 15.8
(n=133)
18.0 (n=66)
96.0 (n=77)
36 (22%)
4 (2%)
57 (35%)
31 (19%)
57 (35%)
112 (68%)
5 (3%)
21 (13%)

0.53
1.47
0.70
1.08
0.84
1.89
1.58
2.25‡

99.5 ± 1.8
(n=176)
86.0 ± 17.4
(n=203)
18.0 (n=113)
95.0 (n=121)
47 (19%)
7 (3%)
80 (32%)
48 (19%)
83 (33%)
180 (72%)
9 (4%)
42 (17%)

1 (1%)

2 (1%)

0.97

3 (1%)

Values are presented as n (%) unless otherwise noted.
*P<0.05, Mann-Whitney test.
†

P=0.02, Mann-Whitney test.

‡

P=0.03, chi-square test with Yates’ correction.

CAP, community-acquired pneumonia; CT, computed tomography; NRP, nonresponsive pneumonia; SD, standard deviation.

3 controls had Legionella antigen testing, 3 controls
had rapid influenza testing, and 1 control had testing
for endemic fungi. There was no significant difference
in the proportion of cases treated with antibiotics at
the initial visit compared to controls (73/85 [86%] vs.
155/165 [94%], P=0.06; Table 4).
All 85 of the NRP patients and 72% (n=119) of control
patients received a follow-up clinical visit. Control
patients who did not receive a follow-up visit had a
mean age of 46.9 ± 16 years, had a current and former
smoking rate of 24% and 13%, respectively, and
an asthma rate of 24%. Rates of all other comorbid
conditions were less than the mean for all 165 control
patients. The average elapsed time for the first followup visit did not differ between groups (7.8 vs. 7.9
days). A second follow-up visit was made by 37% of
controls and 86% of cases, and elapsed times did not
differ (13.0 vs. 12.6 days).
At the first follow-up visit, as one might expect, a chest
X-ray was ordered more often for cases (55%) than
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controls (26%, P<0.001). Ultimately, 41% of eligible
unique controls and 72% of cases received chest X-ray
at the first or second follow-up visit. Ultimately, 10% of
unique controls and 28% of cases received a computed
tomography scan of the chest at the first or second
follow-up visit. Referral for bronchoscopy occurred in
0.6% (1/165) of controls and 7% (7/85) of cases. This
examination revealed bronchiolitis obliterans in the 1
control subject. Bronchoscopy was unrevealing in 2
of the cases, but led to a diagnosis of lung carcinoma
in 2 cases, a diagnosis of tracheobronchomalacia in
another, and diagnoses of Haemophilus parainfluenzae
pneumonia and pseudomonal pneumonia, respectively,
in the remaining 2 cases. A higher proportion of cases
had an antibiotic change at the first (62% vs. 15%,
P<0.001) or second follow-up visit (47% vs. 5%,
P<0.001).
Multivariable binary logistic regression models,
utilizing those predictor variables significantly
associated on univariable analysis, revealed three main
predicators of NRP: former smoker (odds ratio 2.27
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Table 4. Antibiotic regimen prescribed at initial visit

Original antibiotic*
No antibiotic
Extended spectrum macrolide
Quinolone
Amoxicillin or amoxicillin/clavulanic
acid
Cephalosporin (oral)
Doxycycline
Intravenous antibiotics (including
ceftriaxone)
Sulfamethoxazole/trimethoprim
Penicillin

NRP
cases
(N=85)

CAP
controls
(N=165)

9 (11%)
28 (33%)
30 (35%)

8 (5%)
63 (38%)
71 (43%)

5 (6%)

12 (7%)

2 (2%)
1 (1%)

4 (2%)
2 (1%)

8 (9%)

7 (4%)

1 (1%)

0

1 (1%)

0

*5 cases were on two or more first-line antibiotics;
4 controls were on two or more first-line antibiotics.
CAP, community-acquired pneumonia; NRP, nonresponsive
pneumonia.

Table 5. Final diagnosis of controls and cases
CAP
controls

NRP
cases

CAP or pneumonia NOS
Post-obstructive pneumonia
Anaerobic*
Mycoplasma*
Viral*
Cryptogenic
Eosinophilic
Legionella
MRSA
Klebsiella pneumoniae
Haemophilus influenzae
Pseudomonas
Streptococcus pneumoniae
Not pneumonia

152
0
0
6
3
1
0
0
0
0
0
0
1
2

60
3
3
1
0
1
1
2
1
1
2
2
1
7

Total

165

85

Final diagnosis

*Clinically suspected, not cultured.
CAP, community-acquired pneumonia; MRSA, methicillinresistant Staphylococcus aureus; NOS, not otherwise
specified; NRP, nonresponsive pneumonia.

[95% confidence interval 1.23–4.18], P=0.009), initial
presentation to urgent care (2.10 [1.13–3.91], P=0.019)
and symptoms of myalgia (2.79 [1.41–5.52], P=0.003).
Other univariable associations were not significantly
associated with NRP in this model.
The final diagnoses for controls and cases are
summarized in Table 5. A specific organism or
etiologic agent was not identified for the majority
of patients with CAP. Seven case patients were
ultimately diagnosed with something other than
pneumonia (two with acute bronchitis, two
with asthma/bronchospasm and one each with
pulmonary fibrosis, Mycobacterium avium and upper
respiratory infection), and three cases were deemed
postobstructive pneumonia related to non-small cell
lung cancer. Two control patients were ultimately
diagnosed with acute bronchitis and cardiomyopathy,
respectively, rather than pneumonia.

DISCUSSION

Clinical stability and response to initial treatment of
CAP is affected by several factors, including severity
of the disease, comorbid conditions, local and other
end-organ complications, and nonadherence to
treatment guidelines.7,8,11 Criteria for clinical stability,
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as defined by Halm and others, includes normalized
vital signs, adequate oxygen saturation on room air and
oral intake, and normal mental status.19,20 However,
these criteria were essentially determined through
analysis of hospitalized patients and intended for use in
hospitalized pneumonia patients, not patients initially
evaluated and treated as outpatients. For purposes
of our study, we defined NRP in patients initially
evaluated by primary care clinicians in the ambulatory
setting as individuals with CAP who had worsening
vital signs, symptoms or clinical findings after 4 days,
or who did not improve within 10 days, of antibiotic
treatment.
While we agree with Menendez et al. that the issue of
nonresolving pneumonia is complex and the definition
somewhat arbitrary, we also agree that the proposed
definition of NRP listed in his review, “a clinical
syndrome in which local infiltrates clearly begin with
some clinical association of acute pulmonary infection
(that is, fever, expectoration, malaise and/or dyspnea)
and do not resolve in the expected time,” is too
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vague.21 Our choice of a 4-day window of antibiotic
treatment in which there is no further deterioration of
vital signs, symptoms or clinical findings is consistent
with a prospective study of hospitalized CAP patients
by the Menendez group, which observed a median
of 4 days of antibiotic treatment to clinical stability
using criteria similar to Halm.16 Additionally, others
have defined NRP in hospitalized CAP patients
as those with lack of response after 3 to 4 days of
appropriate antibiotic treatment, often with clinical
deterioration.7,8,9,17
The second portion of our definition of NRP, 10 days of
antibiotic therapy without improvement, is consistent
with the observation that 90% of pneumonia-related
hospitalizations in a cohort of 944 CAP patients who
were treated as outpatients occurred within 10 days
of treatment.22 These same authors concluded that
“the incidence of hospitalization within 10 days of
beginning outpatient treatment for CAP is a reasonable
screening tool for unsatisfactory quality of care in this
illness.” Similarly, Low et al. also defined NRP as no
clinical improvement or worsening despite 10 days of
antibiotic therapy.23
Despite a conservative definition of NRP, it was
commonly encountered in our health system among
patients with CAP (34%). This figure is significantly
higher than the 6–25% incidence rates reported
in reviews of almost exclusively hospital-based
studies.7,8,11 A prospective study of 1,424 patients
admitted to 15 Spanish hospitals documented
treatment failure in 15.1% of cases. Early treatment
failure, defined as failure within 72 hours, occurred in
62% of these failures.15 This same group prospectively
studied 453 patients with CAP admitted to two
Spanish hospitals and observed treatment failure in
18%.17 Roson et al. performed an observational study
of 1,383 CAP patients hospitalized in Barcelona.9
Early failure, defined as lack of response or worsening
of clinical or radiologic status at 48–72 hours
requiring changes in antibiotic therapy or invasive
procedures, was experienced by 6% of these patients,
predominantly due to progressive pneumonia.
Another 18% remained febrile at 48–72 hours, but
most responded without change in antibiotic therapy.
A recent retrospective study of 32,324 patients with
CAP hospitalized in non-ICU settings in more than
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100 U.S. hospitals observed a 14.6% initial treatment
failure rate. Treatment failure was defined as receipt
of new antibiotics, exclusive of culture-directed
equivalent substitutions.10 In the aforementioned
study of 944 CAP cases treated as outpatients, 7.5%
of patients were subsequently hospitalized within
30 days.22 This cohort, however, was a methodically
selected low-risk population chosen for ambulatory
treatment.
Causes of our relatively high rate of NRP among
patients with CAP are not entirely clear from this
study. In other studies causes of NRP included (but
were not limited to) the following: overwhelming
or progressive pneumonia, extrapulmonary spread,
unusual, specific or resistant organisms, significant
comorbid conditions, older age, incorrect antibiotic
therapy, and malignant or nonmalignant clinical
entities that present in conjunction with pneumonia
or mimic the presentation of pneumonia (Table
6).7-10,15,16,23,24 These previous studies involved almost
exclusively hospitalized patients. However, in the
previously referenced cohort of selected CAP patients
treated as outpatients (with failure defined as need for
hospitalization), those requiring hospitalization were
older, of higher baseline risk class and had chronic
cardiac and/or lung disease compared to those not
hospitalized.22
Initial severity is an important predictor of slow
response of CAP to treatment and often included in the
various clinical scoring systems such as Pneumonia
Severity Index, CURB-65 or SMART-COP.7,8,25-27
Age, which was not statistically significant in our
multivariable analysis, is included in some pneumonia
severity prediction tools; however, cutoffs range from
65 to 80 years.25,26 In addition to comorbid conditions
and vital signs, certain symptoms (e.g. dyspnea,
confusion) may predict NRP.16 Except for former
smoking history, myalgia, respiratory rate and pulse
oximetry readings (in those for whom this data was
recorded), there were no differences in presenting
signs, symptoms and comorbid conditions between
cases and controls in our study. Nonetheless, cases
received more diagnostic tests at the first visit. Perhaps
this was a result of uncaptured variables such as an
overall clinical impression of greater degree of illness
among the cases.
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Table 6. Causes of nonresponsive pneumonia7-10,15,16,23,24
Host factors

Poor pulmonary toilet
Local or generalized immune deficiency
Major comorbid conditions
Smoking
Chest or lung anatomic abnormalities

Infections and
complications

Resistant organisms
• Pseudomonas aeruginosa
• Methicillin-resistant Staphylococcus
aureus (MRSA)
•β
 -lactamase-producing
Enterobacteriaceae
Inherently slow-resolving organisms
(e.g. Legionella sp.)
Unusual microorganisms
• Mycobacterium sp.
• Nocardia sp.
• Fungi (Aspergillus, Blastomyces,
Histoplasma, Coccidioides)
• Pneumocystis jirovecii
• Anaerobes
Viruses
• Influenza A and B
• Respiratory syncytial virus
• Adenovirus
• Human metapneumovirus
Complications of pneumonia
• Empyema
• Abscess or necrotizing pneumonia
• Metastatic infection
Treatment-related issues
• Incorrect antimicrobial
• Incorrect dose
• Patient intolerance or nonadherence

Noninfections

Neoplasms
Acute respiratory distress syndrome
Pulmonary edema
Pulmonary embolism
Pulmonary hemorrhage
Pulmonary fibrosis
Cryptogenic organizing pneumonia
Eosinophilic pneumonia
Sarcoidosis
Collagen vascular disease
Vasculitis
•G
 ranulomatosis with polyangiitis
(Wegener’s)
• Churg-Strauss

86

JPCRR • Volume 3, Issue 2 • Spring 2016

The association of myalgia with NRP is interesting.
While myalgia may be found among those with
atypical organisms and in some cases of invasive
Streptococcus pneumoniae infections,28 it is common
in patients with influenza, an entity not responsive
to antibacterial agents and which often yields more
severe or prolonged symptoms.29 Historically,
Streptococcus pneumoniae has been the most
commonly identified bacterial etiologic agent of CAP
in adults.25 Haemophilus influenzae, Legionella spp.,
Staphylococcus aureus (including methicillin-resistant
strains [MRSA])26 and gram-negative bacilli cause a
minority of CAP cases. In a Canadian study of CAP
patients who were primarily managed as outpatients,
Mycoplasma pneumoniae, respiratory viruses and
Chlamydophila pneumoniae were also common
etiologies; however, viruses were not sought.30 In a
recent comprehensive study of the etiologic agents of
CAP in hospitalized adults with radiologic evidence
of pneumonia in Chicago and Nashville, a pathogen
was detected in 38% of all cases; one or more viruses
were detected in 23%, bacteria in 11%, bacterial and
viral pathogens in 3% and fungal or mycobacteria
in 1%.31 A similar study in New Zealand observed a
29% viral presumed etiology in hospitalized patients
with CAP. Intriguingly, myalgia was associated with
pneumonia caused by a respiratory virus and with
influenza pneumonia.32 Perhaps our study population
of CAP patients initially evaluated by primary care
clinicians in ambulatory settings includes a significant
proportion of patients with primary viral pneumonia.
Such individuals would be expected to have a slow
or nonresponsive course following onset of antibiotic
treatment (i.e. NRP)33 and may have associated
myalgia.
The majority of primary care clinicians in our study
ordered a chest radiograph –– a “C” recommendation
(consensus, expert opinion) in this setting to confirm
clinically suspected CAP25 –– but no further testing
when CAP was diagnosed in an ambulatory setting.
In a similar patient population, chest radiographs
were ordered in 87.5% of cases given the diagnosis
of CAP by ambulatory primary care clinicians,34 a
figure somewhat higher than in our study (72%). It
is also a “C” recommendation that evaluation for
specific pathogens that would alter standard empiric
therapy should be performed on the basis of clinical
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and epidemiological grounds; testing is usually not
required in outpatients.25 This more pragmatic approach
may decrease unnecessary diagnostic testing but could
potentially delay confirmation of the specific disease
or misdiagnose some patients with similar symptoms
but different illnesses.
In our study, initial empiric antibiotic regimens
were generally within contemporary treatment
guidelines.24,25 Adherence to these guidelines did not
seem to differ between cases and controls and does
not seem to explain the high rate of NRP. The majority
of patients who fulfilled our definition of NRP had an
additional chest radiograph and a change of antibiotics
at the first follow-up visit, actions generally supported
by expert opinion.7,25,26
Limitations
Our retrospective study design allowed for the
observation of clinician behavior and disease
progression regarding patients with CAP presenting
to a primary care clinic, without introducing the
Hawthorne effect,35 but also created certain limitations.
Some pertinent data were not available in medical
records, and patients did not return for follow-up at
defined intervals or at all in some instances. Missing
data could introduce information bias; however, there
was no indication these limitations were more prevalent
among cases than controls. Control patients who did
not make return visits may have skewed the results;
however, these were generally healthy patients deemed
likely to recover and who did not require a return visit
by the treating clinician.
Additionally, although we made a clear definition
of NRP, obtaining a clear picture of the onset of
the disease and eradication of the illness from the
clinical records was difficult for some patients.
It is important to emphasize that this was a study
of patients given the initial diagnosis of CAP by a
primary care clinician in an ambulatory setting.
Subsequent care may have included inpatient or
outpatient consultation or management by specialists.
Some patients did not undergo initial radiologic study
to confirm the diagnosis, and some did have negative
reports. The latter may not preclude the diagnosis
of pneumonia given the lag of radiologic findings
in early pneumonia.36 Nonetheless, patients with

Original Research

nonpneumonic viral infections, for example, may
have been included in the study cohort, and these
entities may have contributed to the percentage of
patients with NRP, given the propensity for the most
common symptom, cough, to last up to 3 weeks,37 and
particularly given the mismatch of cough duration
with patient expectations.38 Lastly, some patients
with self-limited CAP may have been missed on
presentation with respiratory symptoms.37
This study presents opportunities for further research.
Careful prospective studies could perhaps define a
more useful scoring system –– based on presenting
signs, symptoms and comorbid conditions –– for
predicting NRP in patients with CAP treated in the
ambulatory setting. A number of biomarkers have been
considered useful adjuncts for the determination of
bacterial pneumonia diagnosis, severity and treatment
response in some, but not all, studies.7,17,26,39-41 Further
investigations are certainly needed to confirm the
utility of these tests in the patient with CAP who is
evaluated as an outpatient. Similarly, the role of rapid
diagnostic tests for specific respiratory pathogens in
the outpatient setting is still being defined.42 Future
research could explore their utility in CAP to help
assign etiology and to determine proper treatment
and expectations regarding response at the time of
presentation.

CONCLUSIONS

When primary care clinicians initially diagnose
community-acquired pneumonia in an ambulatory
clinic, the majority order chest radiographs but only
a small minority order additional testing for specific
etiologic agents. Risk factors for nonresponsive
pneumonia among those with CAP identified in this
study included former smoking history, symptoms of
myalgia and presentation to urgent care. The presence
of myalgia may be too nonspecific to be useful as a
predictor of NRP; however, it may point toward a viral
etiology, one likely to be nonresponsive to antibiotic
therapy. Careful prospective studies are needed to
determine if the use of serum biomarkers and/or
targeted rapidly available molecular tests for specific
etiologic organisms –– perhaps in conjunction with
presenting signs and symptoms –– at the initial visit
for CAP predicts or prevents NRP in the primary care
ambulatory setting.
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Patient-Friendly Recap
• Community-acquired pneumonia (CAP) is a
common infectious disease.
• When initial treatment with antibiotics fails,
a CAP patient is said to have nonresponsive
pneumonia (NRP). There are a number of
reasons for NRP.
• The authors reviewed cases of NRP in patients
diagnosed in an outpatient clinic (as opposed to
in a hospital setting).
• They found NRP occurs more frequently than
previously thought, and may be more common
among pneumonia patients who have muscle
pain, present to urgent care or used to smoke.
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